MedTrace Logo

Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease

NCT02673164 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2021-01-19

No results posted yet for this study

Summary

The aim of the SCIENCE study is, in an international multicentre double-blind placebo-controlled study, to investigate efficacy of direct intra-myocardial injection of 100 mio. allogeneic Cardiology Stem Cell Centre\_adipose derived stem cells (CSCC\_ASCs) in patients with reduced left ventricular Ejection Fraction (EF) (≤45%) and heart failure.

Conditions

Interventions

BIOLOGICAL

CSCC_ASC

The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)

Sponsors & Collaborators

Principal Investigators

  • Jens Kastrup, Professor MD · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673164 on ClinicalTrials.gov